BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20049422)

  • 1. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
    Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Kim HK; Ryu JS; Kim GS; Lee MC; Chung SJ; Koh JM
    Calcif Tissue Int; 2010 Feb; 86(2):132-41. PubMed ID: 20049422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
    Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
    Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum homocysteine and physical exercise in patients with Parkinson's disease.
    Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
    Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low calcaneal bone mineral density and the risk of distal forearm fracture in women and men: a population-based case-control study.
    Atroshi I; Ahlander F; Billsten M; Ahlborg HG; Mellström D; Ohlsson C; Ljunggren O; Karlsson MK
    Bone; 2009 Oct; 45(4):789-93. PubMed ID: 19539795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
    Camicioli RM; Bouchard TP; Somerville MJ
    Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women.
    Gerdhem P; Ivaska KK; Isaksson A; Pettersson K; Väänänen HK; Obrant KJ; Akesson K
    J Bone Miner Res; 2007 Jan; 22(1):127-34. PubMed ID: 17032146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
    Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
    West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dietary B vitamins on BMD and risk of fracture in elderly men and women: the Rotterdam study.
    Yazdanpanah N; Zillikens MC; Rivadeneira F; de Jong R; Lindemans J; Uitterlinden AG; Pols HA; van Meurs JB
    Bone; 2007 Dec; 41(6):987-94. PubMed ID: 17936100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis.
    Zoccolella S; Simone IL; Lamberti P; Samarelli V; Tortelli R; Serlenga L; Logroscino G
    Neurology; 2008 Jan; 70(3):222-5. PubMed ID: 18195267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.
    Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Ryu JS; Kim GS; Lee MC; Koh JM; Chung SJ
    Mov Disord; 2010 Feb; 25(3):332-40. PubMed ID: 19938151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
    Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V
    J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
    Yuan RY; Sheu JJ; Yu JM; Hu CJ; Tseng IJ; Ho CS; Yeh CY; Hung YL; Chiang TR
    J Neurol Sci; 2009 Dec; 287(1-2):64-8. PubMed ID: 19786283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dietary riboflavin but not folate predicts increased fracture risk in postmenopausal women homozygous for the MTHFR 677 T allele.
    Yazdanpanah N; Uitterlinden AG; Zillikens MC; Jhamai M; Rivadeneira F; Hofman A; de Jonge R; Lindemans J; Pols HA; van Meurs JB
    J Bone Miner Res; 2008 Jan; 23(1):86-94. PubMed ID: 17725378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.
    O'Suilleabhain PE; Bottiglieri T; Dewey RB; Sharma S; Diaz-Arrastia R
    Mov Disord; 2004 Dec; 19(12):1403-8. PubMed ID: 15390053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus.
    Rhew EY; Lee C; Eksarko P; Dyer AR; Tily H; Spies S; Pope RM; Ramsey-Goldman R
    J Rheumatol; 2008 Feb; 35(2):230-6. PubMed ID: 18203323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone density and fracture risk in men.
    Melton LJ; Atkinson EJ; O'Connor MK; O'Fallon WM; Riggs BL
    J Bone Miner Res; 1998 Dec; 13(12):1915-23. PubMed ID: 9844110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications.
    Erzin Y; Uzun H; Celik AF; Aydin S; Dirican A; Uzunismail H
    J Clin Gastroenterol; 2008; 42(5):481-6. PubMed ID: 18344891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures.
    Stone KL; Seeley DG; Lui LY; Cauley JA; Ensrud K; Browner WS; Nevitt MC; Cummings SR;
    J Bone Miner Res; 2003 Nov; 18(11):1947-54. PubMed ID: 14606506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
    Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
    Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.
    Sinigaglia L; Nervetti A; Mela Q; Bianchi G; Del Puente A; Di Munno O; Frediani B; Cantatore F; Pellerito R; Bartolone S; La Montagna G; Adami S
    J Rheumatol; 2000 Nov; 27(11):2582-9. PubMed ID: 11093437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.